Atlas Trials

R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma

Clinical trial NCT02628405 · UNKNOWN

Trial details

NCT number
NCT02628405
Sponsor
Academic and Community Cancer Research United
Status
UNKNOWN
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent Primary Mediastinal (Thymic) Large B-Cell LymphomaRecurrent Transformed Non-Hodgkin LymphomaRefractory B-Cell Non-Hodgkin LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory Primary Mediastinal (Thymic) Large B-Cell LymphomaRefractory Transformed Non-Hodgkin Lymphoma
Start date
2016-05-20
Primary completion
2021-09-24
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.